E-SYNC T Cells for Glioblastoma
This study is testing the safety and side effects of E-SYNC T Cells, a type of CAR T-cell therapy, in people with glioblastoma (a type of brain cancer) that has an EGFRvIII gene mutation. CAR T-cell therapy involves taking your own immune cells (T cells), modifying them in the lab to better fight cancer, and then giving them back to you. Before receiving E-SYNC T Cells, you will have chemotherapy with cyclophosphamide and fludarabine. The study aims to see how well these modified T cells work against the cancer. We are looking for 20 participants, and the current recruitment status is unclear.
- Study design
- This is a dose-escalation study, meaning different groups will receive different doses of E-SYNC T Cells. It involves up to 20 participants with glioblastoma.
- What's involved
- You would undergo leukapheresis (a procedure to collect your blood cells) and potentially surgical removal of tumor tissue. You will also receive intravenous (IV) infusions of E-SYNC T Cells, cyclophosphamide, and fludarabine.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for treatment-emergent adverse events for up to 96 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jennifer Clarke, MD, MPH · STUDY_CHAIR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants reporting treatment-emergent adverse eventsUp to 96 weeks
Treatment-emergent adverse events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0